Evidence map›Paper›PMID 30684075›Full record

ArticleDigestive diseases and sciences2019

Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn's Disease.

Christine A Schad, Bryce E Haac, Raymond K Cross, Ali Syed, Shumet Lonsako, Andrea C Bafford

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Christine A SchadDepartment of Surgery, University of Maryland School of Medicine, 29 South Greene Street, 6th Floor, Baltimore, MD, 21201, USA.
Bryce E HaacDepartment of Surgery, University of Maryland School of Medicine, 29 South Greene Street, 6th Floor, Baltimore, MD, 21201, USA.
Raymond K CrossDivision of Gastroenterology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Ali SyedDivision of Gastroenterology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Shumet LonsakoDivision of Gastroenterology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Andrea C BaffordDepartment of Surgery, University of Maryland School of Medicine, 29 South Greene Street, 6th Floor, Baltimore, MD, 21201, USA. abafford@som.umaryland.edu.
University of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of postoperative anti-TNF therapy on infectious complications following Crohn's disease surgery remains controversial. Use of anti-TNF therapy 2-4 weeks postoperatively appears safe, but safety of use within 2 weeks is unknown.

aimsWe sought to evaluate the effect of anti-TNF therapy initiated within 2 weeks of abdominal surgery in patients with Crohn's disease.

methodsWe conducted a retrospective review of adult Crohn's disease patients undergoing abdominal surgery between 2004 and 2011. Infectious and non-infectious complications were compared between patients exposed to anti-TNF therapy within 2 weeks or between 2 and 4 weeks postoperatively and to those without exposure using chi-squared and regression analysis.

resultsThree hundred thirty-one abdominal surgeries were included; 241 were without anti-TNF exposure, 46 received postoperative anti-TNF within 2 weeks of surgery, and 44 received anti-TNF therapy 2-4 weeks after surgery. Patients who received anti-TNF therapy within 2 weeks of surgery, those initiated between 2 and 4 weeks of surgery, and those who did not receive anti-TNF therapy within 4 weeks of surgery had no significant difference in rates of infectious complications (22%, 32%, 33%, p = 0.332). Rates of non-infectious complications (4%, 9%, 14%, p = 0.143), mortality (0%, 0%, 3%, p = 0.105), hospital readmission (17%, 16%, 15%, p = 0.940), and reoperation (11%, 11%, 16%, p = 0.563) were also similar between groups.

conclusionsUse of early anti-TNF therapy within 2 weeks or between 2 and 4 weeks following abdominal surgery did not increase risk of postoperative surgical infections in Crohn's patients.

Indexed as

AdultCrohn DiseaseDigestive System Surgical ProceduresDrug Administration ScheduleFemaleHumansImmunocompromised HostMaleMiddle AgedOpportunistic InfectionsPostoperative CareRetrospective StudiesRisk AssessmentRisk FactorsSurgical Wound InfectionTime FactorsTNF protein, humanTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAnti-TNFComplicationsCrohn’s diseaseInfectionPostoperative

Identifiers

PMID30684075
OpenAlexW2914045595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.